pSivida announced that the United Kingdom’s National Institute for Health and Care Excellence, or NICE, issued draft guidance recommending ILUVIEN for the treatment of pseudophakic patients with chronic diabetic macular edema considered insufficiently responsive to available therapies. Following a rapid review by NICE, this recommendation proposes a change to the published guidance issued by NICE in January and takes into consideration a patient access scheme submitted by Alimera. NICE will issue final guidance after a comment period. “We are very pleased. If this recommendation becomes final, ILUVIEN will be available in the U.K. to pseudophakic as well as private pay and privately insured patients,” said Dr. Paul Ashton, CEO of pSivida.